Abstract
'Tumour response', defined as clinical or radiological evidence of tumour shrinkage is frequently regarded as an objective of chemotherapy, rather than as a predictor of prolonged survival. This study has assessed whether a fall in the serum CEA concentration after chemotherapy for disseminated colorectal cancer is a predictor of prolonged survival and compared it with tumour response as a predictor of survival. There was a 37% improvement in median survival among patients whose serum CEA concentration fell after chemotherapy (70% of patients treated) compared with patients whose serum CEA did not fall. The use of greater than 25% clinical or radiological tumour shrinkage as a predictor of prolonged survival identified a smaller proportion (36%) of patients in whom there was a 52% prolongation in median survival compared with patients whose tumours shrank less than 25%, or did not shrink. Proportional hazards regression analysis suggested that tumour shrinkage was a stronger predictor of survival. A fall in serum CEA concentration, however, identified a group of patients whose tumours did not shrink, but who had a 27% improvement in median survival compared with those whose tumours did not shrink and whose serum CEA concentration did not fall. Monitoring of the serum CEA during the first two months of treatment appears to provide a sensitive and economical means of identifying those patients whose survival is likely to be prolonged by chemotherapy for colorectal cancer.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Al-Sarraf M., Baker L., Talley R. W., Kithier K., Vaitkevicius V. K. The value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy. Cancer. 1979 Oct;44(4):1222–1225. doi: 10.1002/1097-0142(197910)44:4<1222::aid-cncr2820440409>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
- Anderson J. R., Cain K. C., Gelber R. D. Analysis of survival by tumor response. J Clin Oncol. 1983 Nov;1(11):710–719. doi: 10.1200/JCO.1983.1.11.710. [DOI] [PubMed] [Google Scholar]
- Hansen H. J., Snyder J. J., Miller E., Vandevoorde J. P., Miller O. N., Hines L. R., Burns J. J. Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. Hum Pathol. 1974 Mar;5(2):139–147. doi: 10.1016/s0046-8177(74)80061-4. [DOI] [PubMed] [Google Scholar]
- Herrera M. A., Chu T. M., Holyoke E. D., Mittelman A. CEA monitoring of palliative treatment for colorectal carcinoma. Ann Surg. 1977 Jan;185(1):23–30. doi: 10.1097/00000658-197701000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hine K. R., Dykes P. W. Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA. Gut. 1984 Jun;25(6):682–688. doi: 10.1136/gut.25.6.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kemeny N., Braun D. W., Jr Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med. 1983 May;74(5):786–794. doi: 10.1016/0002-9343(83)91066-5. [DOI] [PubMed] [Google Scholar]
- Lesser M. L., Cento S. J. Tables of power for the F-test for comparing two exponential survival distributions. J Chronic Dis. 1981;34(11):533–544. doi: 10.1016/0021-9681(81)90016-3. [DOI] [PubMed] [Google Scholar]
- Lokich J. J., Ellenberg S., Gerson B. Criteria for monitoring carcinoembryonic antigen: variability of sequential assays at elevated levels. J Clin Oncol. 1984 Mar;2(3):181–186. doi: 10.1200/JCO.1984.2.3.181. [DOI] [PubMed] [Google Scholar]
- Mayer R. J., Garnick M. B., Steele G. D., Jr, Zamcheck N. Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer. 1978 Sep;42(3 Suppl):1428–1433. doi: 10.1002/1097-0142(197809)42:3+<1428::aid-cncr2820420808>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
- Simon R., Lee Y. J. Nonparametric confidence limits for survival probabilities and median survival time. Cancer Treat Rep. 1982 Jan;66(1):37–42. [PubMed] [Google Scholar]